More Weight Loss Predicted for Early Responders to Saxenda
Results from the SCALE Obesity and Pre-diabetes trial showed that adults with obesity or who are overweight with weight-related comorbidities and who had lost ≥4% of their body weight at Week 16 (early responders) had greater weight loss after completing 56 weeks with Saxenda (liraglutide [rDNA origin]; Novo Nordisk) injection along with a reduced-calorie diet and increased physical activity vs. those who had a weight loss of <4% at Week 16 (early nonresponders). These findings were presented at the 24th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE).
The Phase 3a trial is a randomized, double-blind, placebo-controlled, multinational trial in non-diabetic adults (n=3,731) that were randomized to treatment with Saxenda or placebo in combination with a reduced-calorie diet and increased physical activity. The study aimed to examine the efficacy of Saxenda vs .placebo, and to explore the potential long-term efficacy in delaying the onset of type 2 diabetes in patients with pre-diabetes at baseline.
More adults treated with Saxenda were early responders vs. those in the placebo group (77.3% vs. 30.5%). At Week 56, Saxenda early responders who finished the trial achieved a greater average weight loss vs. the early nonresponders (10.8% v s. 3.0%). In addition, waist circumference in early responders vs. early nonresponders was reduced by 10.5cm and 4.8cm, respectively. Early responders also achieved greater improvement across various secondary endpoints, including blood glucose control, cardiometabolic risk factors, and health-related quality of life.
For more information call (844) 363-4448 or visit Saxenda.com.